论文部分内容阅读
目的探索联合应用莫西沙星治疗耐药结核病的效果。方法 46例药敏试验明确确诊的耐药结核病患者,随机分为治疗组23例和对照组23例,分别采取6Mfx ZPto Km PAS/18Mfx ZPto PAS(莫西沙星+吡嗪酰胺+丙硫异烟胺+卡那霉素+对氨基水杨酸)和6Lfx ZPto Km PAS/18Lfx ZPto PAS(左氧氟沙星+吡嗪酰胺+丙硫异烟胺+卡那霉素+对氨基水杨酸)治疗方案,治疗后对两组进行临床疗效对比分析。结果治疗组的痰菌阴转率、病灶吸收率、空洞闭合率均高于对照组,差异均具有统计学意义(P<0.05)。结论联合应用莫西沙星能有效提高耐药结核病的治愈率。
Objective To explore the combined effect of moxifloxacin in the treatment of drug-resistant tuberculosis. Methods A total of 46 patients with drug-resistant TB were randomly divided into treatment group (n = 23) and control group (n = 23). Six patients were randomly assigned to receive 6Mfx ZPto Km PAS / 18Mfx ZPto PAS (moxifloxacin + pyrazinamide + Amine + kanamycin + p-aminosalicylic acid) and 6Lfx ZPto Km PAS / 18Lfx ZPto PAS (levofloxacin + pyrazinamide + prothionamide + kanamycin + p-aminosalicylic acid) After comparing the clinical efficacy of the two groups. Results The sputum negative conversion rate, the absorption rate of the lesion and the void closure rate in the treatment group were all higher than those in the control group, with statistical significance (P <0.05). Conclusion Combined application of moxifloxacin can effectively improve the cure rate of drug-resistant tuberculosis.